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In an effort to increase the credibility of human embryonic stem cell (hESC) lines
established in Korea, obligatory registration was introduced by the Bioethics and
Safety Act 2008, effective as of January 1, 2010.
The DNA fingerprint, chromosome stability, expression of pluripotency markers,
and contamination of mycoplasma of the submitted lines were analyzed by Korea
Centers for Disease Control and Prevention (KCDC). The characterization data
and ethical aspects, such as informed consent for donation of surplus embryos,
were reviewed by a 10-member advisory review committee for stem cell registry.
A total of 55 domestic hESC lines were submitted for registration in 2010; among
them 51 were registered. Among these submitted lines, 26 were additionally
characterized by KCDC, while 25 lines previously characterized by the Ministry of
Education, Science and Technology were not additionally analyzed by KCDC.
Registration completed an oversight system for embryo research by registering
the products of licensed embryo research projects, making embryo research
more transparent in Korea. Information about hESC lines is available at the
website of the Korea Stem Cell Registry (kscr.nih.go.kr).1. Introduction
A recent clinical trial on a stem cell therapy was
initiated using derivatives from embryonic stem cells
(ESCs) [1]. Human ESCs (hESCs) have a wide variety
of possibilities in regenerative medicine, because of
their two advantageous characteristics that distinguish
them from adult stem cells: (1) embryonic stem cells can
differentiate into any type of cell or tissue; and (2)ibuted under the terms o
y-nc/3.0) which permits unr
is properly cited.
ol and Prevention. Publisheembryonic stem cells have the capacity to proliferate
indefinitely under optimal conditions. However, there
are several obstacles in the use of hESCs that need to be
overcome before they can be used in regenerative
medicine. In addition to the scientific aspects, such as
accurate control of proliferation and purity of differen-
tiated cells, the reliability of the cell line is an ethical
issue. This is because hESCs originate from human
embryos. As the need for comprehensive informationf the Creative Commons Attribution Non-Commercial License
estricted non-commercial use, distribution, and reproduction in
d by Elsevier. All rights reserved.
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increased, several countries and groups established
hESC registries [2,3]. The European registry, hESCreg
(http://www.hescreg.eu/), was founded as a collabora-
tive and interdisciplinary platform where researchers
and the general public can access information about
available hESC lines. The international stem cell
registry at the University of Massachusetts Medical
School (http://www.umassmed.edu/iscr/) has been
continuously expanding its database since its launch in
2008, and currently has information on >400 hESCs and
120 induced pluripotent stem cells (iPSCs). In accor-
dance with an order from the President of the United
States. The National Institute of Health (NIH) has
registered 91 hESC lines eligible for federal funding
since 2009 (http://stemcells.nih.gov/research/registry).
These registries provide information through their
websites with features relevant to their own purposes.
Several scientists have been active in the production
of hESC lines in Korea [4,5]. Approximately 60 hESC
lines have been known to be established in Korea.
Although the Bioethics and Safety Act has been effec-
tive since 2005, the exact information about hESC lines
was not available. To improve the credibility of hESC
lines that have been established and used in Korea, an
obligatory registration was initiated on January 1, 2010
according to the Bioethics and Safety Act 2008. Here,
we report the first 1-year results of the registration.2. Materials and Methods
2.1. Cell culture
The hESC line H9 was cultured on STO (ATCC
Manassas, VA, USA) feeder in 80% DMEM/F12
medium (Gibco, Carlsbad, CA, USA) supplemented with
20% KO serum (Gibco), 0.1 mM nonessential amino
acids (Gibco), 0.1 mM b-mercaptoethanol (Gibco), and
4 ng/mL bFGF (Invitrogen). The STO feeder cells were
maintained in DMEM medium containing 10% FBS
(Gibco), and used after mitotic inactivation by mito-
mycin C (Sigma, St. Louis, MO, USA). H9 cells were
passaged every 5e7 days with 2 mL/mL ROCK inhibitor
(Sigma), and the culture medium was changed daily. The
submitted hESC lines were minimally cultured in their
own media. The human fibroblast cell line IMR-90
(ATCC) was maintained in DMEM medium containing
10% FBS and 1% penicillin/streptomycin (Gibco).
2.2. DNA fingerprinting
The identity of the hESC line was analyzed by short
tandem repeat (STR) analysis. The hESC colonies were
removed from the surface of the culture dish and
collected in a 15-ml conical tube. The STR analyses
were performed by DowGene (Seoul, Korea) and
Kogene (Seoul, Korea); both companies used a Power-
plex 16 system (Promega). The STR data of thesubmitted hESC lines were compared with those of
other lines with clustering software R and Microsoft
Excel.
2.3. Karyotyping
Karyotyping of hESCs was conducted by GenDix
(Seoul, Korea) and Samkwang (Seoul, Korea). For
karyotyping, a 4-well dish of each cell line was analyzed
by GTG-banding method.
2.4. RT-PCR
Total RNA was isolated using Trizol (Invitrogen)
according to the manufacturer’s protocol. Subsequently,
cDNA was synthesized from 1 mg of the total RNA by
PrimeScript 1st strand cDNA synthesis kit (TAKARA).
Quantitative real-time PCR (qRT-PCR) was performed
with TaqMan assays (Applied Biosystems) and Gene
Expression probes (Applied Biosystems; GAPDH,
Hs99999905_m1; NANOG, Hs02387400_g1; OCT4,
Hs00742896_s1; SOX2, Hs00602736_s1; TERT,
Hs00162669_m1). qRT-PCR was performed using
TaqMan Universal PCR Master Mix and ABI 7500
Real-Time PCR System (Applied Biosystems). Expres-
sion levels were analyzed by DDCt method. All reac-
tions were duplicated.
2.5. Mycoplasma tests
Two methods were used to estimate mycoplasma
contamination in the hESCs. Tests were performed
immediately after receiving cells from applicants. For
PCR detection, PCR Mycoplasma Detection Set
(TARAKA) was used with 0.5 mL ES culture media. For
enzymatic detection, MycoAlert Mycoplasma Detection
Kit (Lonza, Basel, Switzerland) was used with 100 mL
ES culture media. Fresh ES culture media and positive
control contained in the kit were used as controls. The
amplified PCR products were analyzed by gel electro-
phoresis with 1% agarose gels. Enzymatic reactions
were analyzed by Sirius L tube Luminometer (Berthold,
Pforzheim, Germany).3. Results
3.1. Procedure for registration
The registration procedure is shown in Figure 1. A
stem cell scientist submitted application forms with
copies of informed consent for use of surplus embryos.
After a pre-review of the submitted files by the advisory
review committee, we requested and analyzed the hESC
lines. We analyzed DNA fingerprints, karyotypes, plu-
ripotency markers, and mycoplasma contamination. The
submitted files and our analyzed data were reviewed by
the advisory review committee, which consisted of
seven stem cell scientists, one bioethics professor, and
two government employees. We had four committee
KCDC
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Figure 1. Registration procedure for hESC lines in Korea. KCDC runs the registry and the advisory committee reviews the
submitted data for the registry.
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in 2010.
3.2. Informed consent
The Bioethics and Safety Act has been in effect since
2005. According to this act, only surplus embryos
should be used for research. Therefore according to the
provisions of this act, fertility clinics need to obtain
informed consent from patients before the surplus
embryos can be used for research. The registration
indicated that 29 hESC lines were established from 917
surplus frozen embryos donated from 151 patients since
2005. It is now confirmed that all hESC lines were
established from surplus embryos that have been
provided by patients, with their informed consent, since
2005.
3.3. Analyses of hESC lines
Among 51 registered hESC lines, we analyzed the
DNA fingerprint, karyotype, expression of pluripotency
markers, and mycoplasma contamination of 27 lines.
We harvested and analyzed hESCs as soon as the cells
were submitted, but the cells were maintained for 1e2
days if the amount of cells available was insufficient for
analyses. Another 25 lines were verified by the Ministry
of Education, Science and Technology (MOEST) and
were not additionally analyzed by us. A summary of the
verified data is shown in Table. DNA fingerprinting
using short tandem repeat (STR) analyses showed
that all except analyzed lines except for one line are
independent lines (Table). Among the 27 lines analyzed
by us, three lines showed abnormal karyotypes
(Figure 2AeD). Expression of pluripotency marker
genes was detected in all the tested lines, although the
expression levels of several pluripotency markers of an
aneuploid hESC line (CHA-hES 16) were relatively
lower than those of other hESC lines (Figure 2E).
Mycoplasma contamination tests were performed twice
if the first analysis yielded positive results. Eight lines
were mycoplasma-positive in the first analysis and wereresubmitted. Two lines were still mycoplasma-positive
in the second analysis of submitted cells, while the
other lines were negative in the second analysis of
submitted cells, as shown in Table.
4. Discussion
The Korea hESC registry was founded to ensure that
hESC research in Korea is ethically responsible and
conducted in accordance with the Bioethics and Safety
Act by providing reliable information about hESC lines.
Our registry is enforced by the Bioethics and Safety Act
2008; under this act, registration of hESC lines is
obligatory in Korea. The obligatory registration system
is feasible in Korea because researchers who want to use
human surplus embryos are required to obtain a license
from the MOHW, and the hESC line is thus a product of
licensed research. The Bioethics and Safety Act has
been in effect since 2005, and obligatory registration
started in 2010.
As a result of the registration, we confirmed that 29
hESC lines established after 2005 were from 917 surplus
embryos obtained with informed consent. Among the 55
submitted lines, two lines could not be registered, and
two other lines are under review. Dr. Hwang’s Sooam-
hES1 (also known as NT-1) line was ineligible for
registration because of the unethical aspects revealed by
the report of the investigation committee of Seoul
National University [6]. In addition, NT-1 was revealed
to be a product of parthenogenesis [6,7], which is not
allowed under the Bioethics and Safety Act. Another
hESC line that could not be registered is AMC-1, which
showed the same DNA fingerprint as a previously
established hESC line (Miz-hES4). When we requested
the researchers to submit early passage of AMC-1, we
were informed that it failed to grow. Among the 51
registered lines, 10 lines have abnormal karyotypes,
as shown in Table. The hESC lines with abnormal
karyotypes might be used as models of aneuploid
chromosomal syndrome [8e10].
Table. Summary of analyses of hESC lines submitted in 2010
a
Names of hESC
linesb Year
Submitted data KCDC-analyzed data
RegisteredKaryotype STR
Immuno-
staining
RT-
PCR Mycoplasma
EB or
teratoma
Copies
of informed
consents
List of
surplus
embryos Karyotype STR
Immuno-
staining
RT-
PCR Mycoplasma
1 SNUhES1 2001 46, XY or
47, XY,þ12
O þ þ  Teratoma Oc Yes
2 SNUhES2 2001 46, XX O þ þ  Teratoma Oc Yes
3 SNUhES3 2001 46, XY O þ þ  Teratoma Oc þc þc Yes
4 SNUhES4 2003 46, XY O þ þ  Teratoma Oc þc þc Yes
5 SNUhES5 2004 47, XY,þ16 O þ þ  Teratoma Oc Yes
6 SNUhES6 2004 46, XY O þ þ  EB Oc Yes
7 SNUhES7 2004 46, XY O þ þ  Teratoma Oc Yes
8 SNUhES10 2004 69, XXX O þ þ  EB Oc Yes
9 SNUhES11 2004 46, XY O þ þ  Teratoma Oc þc þc Yes
10 SNUhES12 2004 46, XX O þ þ  EB Oc Yes
11 SNUhES14 2004 46, XY O þ þ  EB Oc Yes
12 SNUhES16 2004 46, XY O þ þ  Teratoma Oc þc þc Yes
13 SNUhES18 2004 46, XY or
47, XY,þ12
O þ þ  Teratoma Oc Yes
14 SNUhES19 2004 46, XY or
47, XY,þ12
O þ þ  Teratoma Oc Yes
15 CHA-hES 3 2005 46, XY O þ þ  Teratoma O O Oc þc þc Yes
16 CHA-hES 4 2004 46, XY O þ þ  Teratoma O O Oc þc þc Yes
17 CHA-hES 5 2004 46, XY, inv(9) O þ þ  Teratoma O O Oc Yes
18 CHA-hES 6 2004 46, XX O þ þ  Teratoma O O Oc Yes
19 CHA-hES 7 2004 46, XX O þ þ  Teratoma O O Oc Yes
20 CHA-hES 8 2004 46, XX O þ þ  Teratoma O O Oc Yes
21 CHA-hES 9 2004 46, XX O þ þ  Teratoma O O Oc þc þc Yes
22 CHA-hES 10 2005 46, XY O þ þ  Teratoma O O Oc Yes
23 CHA-hES 11 2005 46, XY O þ þ  Teratoma O O Oc Yes
24 CHA-hES 12 2005 46, XY O þ þ  Teratoma O O Oc Yes
25 Miz-hES4 2003 46, XY O þ þ EB Oc þc þc Yes
26 CHA-hES 13 2007 46, XX O þ þ  Teratoma O O 46, XX O þ d Yes
27 CHA-hES 14 2007 46, XY O þ þ  Teratoma O O 46, XY O þ d Yes
28 CHA-hES 15 2007 46, XY O þ þ  Teratoma O O 46, XY O þ  Yes
29 CHA-hES 16 2007 71, XXY O þ þ  O O 70, XXY,þ12 O þ d Yes
30 CHA-hES 17 2007 46, XY O þ þ  Teratoma O O 46, XY O þ d Yes
31 CHA-hES 19 2007 47, XX, der(2),
-4,þ5,þmar
O þ þ  O O 47, XX, t(2;4)
q(11.2;p15.2),þ5
O þ d Yes
32 CHA-hES 20 2007 46, XY O þ þ  Teratoma O O 46, XYe O þ  Yes
33 CHA-hES 21 2008 46, XX O þ þ  Teratoma O O 46, XX O þ  Yes
34 CHA-hES 23 2008 46, XX O þ  Teratoma O O 46, XX O þ  Yes
35 CHA-hES 24 2008 46, XY O þ þ  Teratoma O O 46, XY O þ  Yes
36 CHA-hES 26 2008 Tri- or
tetraploidy
O þ  O O 90, XXXX,-6,
-18,add(20)
O þ  Yes
37 SNUhES31 2009 46, XY O þ þ EB O O 46, XY O þ d Yes
38 CHA-hES 18 2007 46, XX O þ þ  Teratoma O O 46, XX O þ  Yes
39 CHA-hES 22 2008 46, XX O þ þ  Teratoma O O 46, XX O þ  Yes
40 CHA-hES 25 2008 46, XX O þ  Teratoma O O 46, XX O þ  Yes
41 CHA-hES M1 2008 46, XX O þ þ  Teratoma O O 46, XX O þ  Yes
42 CHA-hES R1 2008 46, XY O þ þ  Teratoma O O 46, XY O þ  Yes
43 CHA-hES R2 2008 46, XX O þ þ  Teratoma O O 46, XX O þ  Yes
44 CHA-hES R3 2008 46, XX O þ þ  Teratoma O O 46, XX O þ  Yes
45 CHA-hES R4 2008 46, XY O þ þ  Teratoma O O 46, XY O þ  yes
46 CHA-hES B1 2009 46, XY O þ þ  Teratoma O O 46, XY O þ  Yes
47 CHA-hES B2 2009 46, XX O þ þ  Teratoma O O 46, XX O þ  Yes
48 CHA-hES B3 2009 46, XY O þ þ  Teratoma O O 46, XY O þ  Yes
49 AMC-1 2006 46, XY þ þ Teratoma O O 46, XY Of þ  No
50 JNU-hES-01 2009 46, XY O þ þ Difh O O 46, XY O þ þg Yes
51 JNU-hES-02 2009 47, XY,þ12 O þ þ Difh O O 46, XY O þ þg Yes
52 MB01 2002 46, XY þ þ Under
review
53 MB06 2004 46, XY þ þ Under
review
54 Sooam-hES1 2003 46, XX O þ þ  Teratoma No
55 SNUhES32 2010 46, XY O þ þ  EB O O 46, XY O þ  Yes
aIs the submitted number in the order of the review; bRegistered lines are indicated with bold; cAnalyzed by MOEST; dMycoplasma-positive in analysis of first submitted cells, but negative in analysis of second submitted cells;
eAbnormal karyotype in analysis of first submitted cells, but normal in analysis of second submitted cells; fSame STR with Miz-hES4; gMycoplasma-positive in analyses of first and second submitted cells; hDifferentiation data.
Figure 2. Characteristics of three hESC lines with abnormal karyotypes. (A) Normal karyotype of H9. (B) Abnormal karyotype
(70, XXY,þ12) of CHA-hES 16. (C) Abnormal karyotype (47, XX, t(2;4)(q11.2;p15.2),þ5) of CHA-hES 19. (D) Abnormal
karyotype (90, XXXX,-6,-18,add(20)) of CHA-hES 26. (E) The relative quantities of pluripotency marker genes were detected by
real-time PCR using Taqman probe. CHA-hES 16 showed lower levels of expression of several pluripotency markers, whereas
other abnormal lines showed normal expression patterns. H9 was used as a positive control; mock and human fibroblasts were used
as negative controls.
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Registration of human embryonic stem cell lines 147Recently, methods for establishing an iPSC line were
developed [11,12]. iPSCs have characteristics similar to
hESCs with respect to their pluripotency and self-
renewal capacity. Human iPSCs have been recognized
as a good model system for genetic diseases and drug
screening [13]. We are considering the registration of
human iPSC lines to provide information to the scien-
tific community using the hESC registration system. The
registration of human iPSC lines will be optional, not
obligatory. We hope that this registry (kscr.nih.go.kr)
promotes transparency of stem cell research in Korea.
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